COVID-19 March 24, 2020 Federal Update

Legislation
Supplemental III – “COVID-III”

The hope continues to be that a deal can come together, that a time agreement can be reached, and that the Senate can vote expeditiously – if not yesterday night, then certainly by today. Absent any deal, the Senate would vote on cloture on the motion to proceed to the COVID-III vehicle one hour after convening tomorrow.

If the Senate passes the package today, the House could pass by unanimous consent on Thursday. If unanimous consent isn’t achievable, the fallback is the suspension calendar on Friday. All of this is dependent on how quickly a deal is reached and text is released.


Process and Politics:

Multiple caucus conference calls were held yesterday and it seems that both caucuses are attempting to marshal their members toward acceptance of passing the bill by unanimous consent in the House. Speaker Pelosi and other House leadership have indicated they would be willing to pass the bill in the House under unanimous consent, but only if the end product is acceptable.


Policy:

Multiple updated drafts of the bill have been circulated yesterday. However, it’s unclear as of right now, as negotiations are still ongoing, what provisions in the draft bill are completely set and what is being further negotiated. As with previous big deals, nothing is final until everything is final . All policies previously discussed continue to be on the table and could be part of a final deal. CARES text (as of earlier today) here. Latest information indicates a final bill may include the following:

  • $1,200 in direct payments, $500 per child with income limitations and restriction;
  • Early withdrawals from retirement accounts without penalty;
  • Expansion of unemployment insurance (includes eligibility to self-employed, contract employees) for 4 months;
  • Delay in payroll taxes by one year, payable over two years;
  • Net Operating Loss from tax years 2018, 2019, or 2020 may be carried back five years;
  • Small business bridge loans to companies with 500 employees or fewer with a maximum loan of $10 million, administered by 7(a) lenders;
  • $100 billion for hospitals with $50 billion in extra support for combatting COVID-19;
  • Expansion of HSAs to cover over the counter medicine;
  • Telehealth flexibility;
  • Suspension of the Medicare sequester through December 31, 2020. 
  • Liability protections for doctors practicing across state lines;
  • Treasury-administered loans for distressed industries, including $50 billion for passenger airlines, $8 billion for cargo carriers, $10 billion for AIP, with restrictions and a certain amount of oversight (unclear what that is until we see text).

Passed Legislation

Supplemental II – Families First Coronavirus Response Act (HR 6201)

The Senate passed the bill 90-8 Wednesday afternoon and the President signed the bill into law that evening. Bill text here. Factsheet here. Bill section by section here. A summary of paid leave provisions, incorporating changes made by technical correction, is  here.

Supplemental I – Coronavirus Supplemental

Signed by the President March 6. Text here, summary here.


Members of Congress in Quarantine or Treatment

Tested Positive (3): Sen. Rand Paul (R-KY), Rep. Ben McAdams (D-UT), Rep. Mario Diaz-Balart (R-FL)

Currently Self-Quarantined (26): Rep. Paul Gosar (R-AZ), Rep. Julia Brownley (D-CA), Rep. Jason Crow (D-CO), Rep. Matt Gaetz (R-FL), Rep. Mario Diaz-Balart (R-FL), Rep. Doug Collins (R-GA), Rep. Steve Scalise (R-LA), Rep. Ann Wagner (R-MO), Rep. Sharice Davids (D-KS), Rep. Ben Ray Luján (D-NM), Rep. Kathleen Rice (D-NY), Rep. Kendra Horn (D-OK), Rep. Matt Cartwright (D-PA), Rep. Ben McAdams (D-UT), Rep. Gwen Moore (D-WI), Rep. Frederica Wilson (D-FL), Rep. Stephanie Murphy (D-FL), Rep. Drew Ferguson (R-GA), Rep. Joe Cunningham (D-SC), Rep. Tom Cole (R-OK), Rep. David Schweikert (R-AZ), Rep. Anthony Brindisi (D-NY), Rep. David Price (D-NC), Rep. Andy Kim (D-NJ), Sen. Rick Scott (R-FL), Sen. Cory Gardner (R-CO), Sen. Mike Lee (R-UT), Sen. Mitt Romney (R-UT)

Completed Quarantine (4): Sen. Ted Cruz (R-TX), Rep. Mark Meadows (R-NC), Sen. Lindsay Graham (R-SC), Rep. Don Beyer (D-VA)

August 7, 2026
One of the biggest benefits of becoming a Georgia Life Sciences Student Member is access to discounted registration for Georgia's premier life sciences conference—bringing together CEOs, researchers, entrepreneurs, investors, and innovators from across the state. Better yet, Student Membership is only $25 per year , making it one of the best investments you can make in your future. The Georgia Life Sciences Emerging Leaders Network (ELN) is the official student membership community of Georgia Life Sciences, created to connect students, postdoctoral researchers, and early-career professionals with Georgia's thriving life sciences ecosystem. As an ELN member, you'll build meaningful peer-to-peer relationships, engage with industry leaders, explore career opportunities, and gain access to professional development programs designed to help you launch a successful career in the life sciences. As a member, you'll have opportunities to: Connect with fellow students, postdocs, and emerging professionals from across Georgia. Expand your network through peer-to-peer engagement and professional networking events. Learn from industry leaders and gain exposure to Georgia's life sciences ecosystem. Participate in workforce and career development programming. Access Career Connections Student members also receive exclusive access to the Georgia Life Sciences Career Connections LinkedIn Group , where you can: Discover internships and job opportunities. Connect with employers, recruiters, and industry professionals. Stay informed about career fairs, networking events, and workforce initiatives. Engage with a growing community of future life sciences leaders. Student Member Benefits Georgia Life Sciences Student Membership: $25/year Georgia Life Sciences Summit Registration: $150 Access to the Emerging Leaders Network Career Connections LinkedIn Group Networking events and professional development opportunities Industry news, workforce resources, and member communications Whether you're exploring careers in biotechnology, medical devices, pharmaceuticals, diagnostics, digital health, or research, Georgia Life Sciences connects you to the people and opportunities that can help shape your future. Join today . Build your network. Advance your career.
August 6, 2026
From breakthrough therapeutics to next-generation medical technologies, tomorrow's innovators take the stage at the Georgia Life Sciences Summit. Sponsored by Johnson & Johnson, the Startup Showcase will highlight eight of Georgia's most promising early-stage life sciences companies as they present their innovations during the Summit Luncheon on August 26. These emerging companies are tackling some of healthcare's biggest challenges across therapeutics, diagnostics, AI, and medical technology, while demonstrating the depth of innovation taking place throughout Georgia's life sciences ecosystem. Meet the 2026 Startup Showcase Companies: Abundance Biopharma Corporation Athna Biotech Atomistic Insights NovAb Nytricx Oridivus TremeBio YoungHeartValve Following the presentations, each company will participate in a live investor Q&A featuring an exceptional panel of venture leaders: Emily Dinu, Numinous Capital John Gutierrez, Ascenta Capital Dr. Emma Heckenberg, Solas BioVentures Patrick Jordan, NovaQuest Capital Management Tim Opler, Stifel Whether you're an investor looking for the next breakthrough, a corporate leader seeking innovative partners, or simply interested in the future of life sciences, the Startup Showcase offers a front-row seat to the companies poised to shape what's next. Join us August 25–26 at the Georgia Life Sciences Summit and discover the next generation of innovators driving Georgia's life sciences economy.
July 24, 2026
July 24, 2026, Atlanta, GA - Georgia Life Sciences applauds Congressman Rich McCormick (R-GA) for introducing the Biotechnology Diplomacy Leadership Act , legislation designed to strengthen America's leadership in biotechnology by establishing a senior biotechnology leadership position within the U.S. Department of State. As biotechnology continues to drive breakthroughs in healthcare, agriculture, advanced manufacturing, and national security, the United States must remain a global leader in innovation while strengthening strategic partnerships with allies around the world. The proposed legislation recognizes biotechnology as a critical component of U.S. economic competitiveness and foreign policy and would help ensure that the federal government is well positioned to advance these priorities internationally. The legislation also reflects recommendations from the National Security Commission on Emerging Biotechnology , which called for a more coordinated national approach to advancing biotechnology and protecting U.S. leadership in this strategically important sector. "Georgia is home to one of the nation's fastest-growing life sciences ecosystems, and policies that strengthen America's global biotechnology leadership directly benefit innovators, researchers, manufacturers, and patients," said Maria Thacker Goethe, President & CEO of Georgia Life Sciences. "We appreciate Congressman McCormick's leadership in recognizing biotechnology as both an economic engine and a strategic national priority." Georgia Life Sciences looks forward to working with policymakers at both the federal and state levels to advance policies that foster innovation, strengthen the U.S. bioeconomy, and ensure America remains the global leader in biotechnology.
MORE POSTS